Primary sclerosing cholangitis (PSC) is a disease affecting the bile ducts that can lead to end-stage liver disease and cholangiocarcinoma. Patients with this disease lack therapeutic treatment other than liver transplantation.

Noncoding RNAs, such as long noncoding RNAs (lncRNAs), are important regulators and markers of cardiovascular diseases. Saphenous veins are frequently used in coronary artery bypass surgery, but about 50% of the saphenous vein grafts fail in the first 10 years after surgery due to neointima formation.

Investigators at the University of Copenhagen and affiliated organizations presented data from a study that aimed to validate differentially expressed genes (DEGs) in mesial temporal lobe epilepsy (mTLE) as potential new targets.

Researchers from Washington University presented data from a study that aimed to identify myeloid-derived suppressor cell (MDSC) markers in patients with multiple sclerosis (MS).

G protein-coupled receptor 183 (GPR183/EBI2) is one of the key regulators of the innate immune system, and it has been shown to be upregulated in multiple sclerosis (MS) plaques. In a recently reported study, researchers from Medical University of Gdansk evaluated the effects of pharmacological modulation of GPR183 signaling on remyelination.

Reduced expression of nuclear factor erythroid 2-related factor 2 (Nrf2) is observed in humans and animal models of Alzheimer’s disease (AD), with its activation being a promising therapeutic approach.

T-cell activation and function depend on Ca2+ signals and Ca2+ influx after antigen binding to the T-cell receptor (TCR) is mediated by store-operated Ca2+ entry (SOCE) through Ca2+ release-activated Ca2+ (CRAC) channels in the plasma membrane.

Tavros Therapeutics Inc. and Vividion Therapeutics Inc., a subsidiary of Bayer AG, have entered into a collaboration agreement to discover or target four oncology targets across an initial 5-year term.